Abstract: The present invention relates to a system for collecting and preparing a body fluid sample, the system comprising a sample container (10) comprising a sample cup (38) for receiving the sample, said sample cup comprising graduated indicator markings (14) corresponding to equal increments of sample volume, a removable lid (16) for sealably covering said sample cup, said lid having an access point which is sealed by a septum, and a removable cap (22) which is effective to cover said access point, and a delivery device for containing a plurality of predetermined reagent doses which are to be added to a sample within the sample container in the predetermined doses relative to the volume of the sample.

Abstract: The present invention encompasses methods of employing inhibitors of IL-9 in the treatment of fibrotic disorders, e.g., COPD and inflammatory bowel disease.

Abstract: A flotation device for attachment to a small object to prevent the object from sinking if it is dropped into a body of liquid and for allowing the user to quickly and easily retrieve it. The device comprises a float formed of buoyant material and having a longitudinally oriented opening therethrough, a lanyard having its free ends attached together and fixed within said opening so as to form a loop portion about the float, and a spring-biased clip attached to the loop and attachable to the object to be prevented from sinking in a pool of liquid.

Abstract: A flotation device for attachment to a small object to prevent the object from sinking if it is dropped into a body of liquid and for allowing the user to quickly and easily retrieve it. The device comprises a float formed of buoyant material and having a longitudinally oriented opening therethrough, a lanyard having its free ends attached together and fixed within said opening so as to form a loop portion about the float, and a spring-biased clip attached to the loop and attachable to the object to be prevented from sinking in a pool of liquid.

Abstract: The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL-13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for the prevention, management, treatment or amelioration of an inflammatory condition associated with the upregulation of a C/CLP or one or more symptoms thereof and/or the inhibition of IL-13 mediated inflammation.

Abstract: A child carrier is provided. The child carrier has independently adjustable shoulder and waist straps that allow interchangeable use on either hip of the user. The child carrier has a removable storage container that is selectively connectable thereto.

Abstract: The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managinge, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present ivnention encompasses combination therapies, pharamceutical compositions, articles of manufacture, and kits.

Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype (e.g.

Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.